Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study

Area of Science:

• Virology
• Infectious Diseases
• Pharmacogenomics

Background:

• Antiretroviral resistance testing is crucial for managing virological failure in HIV patients.
• Optimal clinical methods for resistance testing remain undetermined.
• This study compares two resistance testing approaches: recombinant viral phenotype and virtual phenotype.

Purpose of the Study:

• To compare the clinical utility of recombinant viral phenotype testing versus virtual phenotype interpretation for guiding antiretroviral therapy in HIV patients with virological failure.
• To assess the effectiveness of each method in achieving HIV RNA suppression.

Main Methods:

• A prospective, randomized, double-blind, multicentre trial involving 300 HIV-infected adults with viral loads > 1000 copies/ml.
• Patients were randomized to either recombinant viral phenotype or virtual phenotype testing.
• Primary outcome was HIV RNA suppression (< 400 copies/ml) at 24 weeks, with extended analysis at 48 weeks.

Main Results:

• After 24 weeks, 46.8% in the phenotype group and 56.2% in the virtual phenotype group achieved HIV RNA < 400 copies/ml (P = 0.1).
• The virtual phenotype group showed a greater mean decrease in viral load (1.3 log copies/ml vs. 1.0 log copies/ml, P = 0.017).
• Multivariate analysis confirmed virtual phenotype's association with greater viral load reduction, adjusted for baseline RNA and adherence (P = 0.0063).

Conclusions:

• Virtual phenotype testing is a viable and effective alternative to recombinant viral phenotype testing for optimizing antiretroviral therapy in treatment-experienced HIV patients.
• Both methods demonstrate utility, but virtual phenotype shows a trend towards better viral load control in this study.
• The findings support the use of virtual phenotype as an effective tool in clinical practice for managing complex HIV cases.